Differential Outcomes in Codon 12/13 and Codon 61 <i>NRAS</i> -Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with <i>NRAS</i> -Mutated Tumors

Abstract

Single-agent binimetinib did not show promising efficacy in <i>NRAS</i>-mutated cancers. The observation of increased OS and PFS in patients with codon 61 <i>NRAS</i>-mutated colorectal cancer merits further investigation.